NCT00663065终止1 期
An Ascending Multiple-Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of PAZ-417 Administered Orally to Elderly Subjects
Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点目标入组 40 人开始时间: 2008年4月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 40
- 主要终点
- safety as determined by adverse events, ECGs, vitals signs, and laboratory test results
研究概览
简要总结
This is study to determine the safety of PAZ-417 in healthy adults over 65.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 65 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
arm 1
Experimental
干预措施: PAZ-417 (Drug)
结局指标
主要结局
safety as determined by adverse events, ECGs, vitals signs, and laboratory test results
时间窗: 6 months
次要结局
- Drug distribution in the blood(6 months)
研究者
相似试验
已完成
不适用
Study Evaluating PAZ-417 in Healthy Young/ElderlyAlzheimer DiseaseNCT00366288Wyeth is now a wholly owned subsidiary of Pfizer56
终止
1 期
Study Evaluating Multiple Ascending Dose in Schizophrenia PatientsHealthyNCT00620568Wyeth is now a wholly owned subsidiary of Pfizer32
已完成
1 期
Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of MYO-029HealthyNCT00563810Wyeth is now a wholly owned subsidiary of Pfizer72
已完成
不适用
Study to investigate the effects and safety of ENX-102 in healthy volunteers.ENX-102 is a new research drug that is being developed for the treatment of neuropsychiatric disorders.Nervous System DiseasesISRCTN61386931Engrail Therapeutics, Inc40
已完成
1 期
A Study of LY3493269 in Healthy ParticipantsHealthyNCT04682106Eli Lilly and Company40